通过R包提供阿尔茨海默氏症临床研究数据:Alzverse
Michael C Donohue1, Kedir Hussen1, Oliver Langford1
1Epstein Family Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|January 29, 2026
概括
新的R数据包简化了对阿尔茨海默病 (AD) 临床研究数据的访问. 这些工具增强了数据共享,促进了可复制性,并通过协作和透明度加速了AD研究.
科学领域:
- 神经科学是一个神经科学.
- 生物医学信息学 生物医学信息学
- 临床研究 临床研究
背景情况:
- 分享临床研究数据对于推进阿尔茨海默病 (AD) 研究至关重要.
- 现有的挑战包括数据可访问性,标准化,文档,可用性和可重复性.
- 克服这些障碍对于加速AD研究进展至关重要.
研究的目的:
- 开发R数据包,以简化访问精心策划的阿尔茨海默病临床研究数据集.
- 为关键的AD研究创建便携式,分析准备的数据资源.
- 促进元分析,促进AD研究中的合作,透明度和可重复性.
主要方法:
- 开发了R数据包 (A4LEARN, ADNIMERGE2) 来提供来自主要AD研究的精选数据集,如A4, LEARN和ADNI.
- 将数据,文档和可重复的分析图片捆绑到便携式,分析准备的格式中,可以安装在R.
- 引入了alzverse包,以应用一个共同的数据标准,整合研究特定的包用于元分析.
主要成果:
- 创建了R包 (A4LEARN, ADNIMERGE2),提供来自阿尔茨海默病显著临床试验和观察研究的可访问,精心策划的数据集.
- 这些包提供了分析准备的数据,文档和可重复的分析图片.
- 阿尔兹维尔斯软件包通过共同的标准统一数据,使综合分析和元分析成为可能.
结论:
- R数据包提供了一个可扩展的框架,以加速阿尔茨海默病的临床研究.
- 这些工具增强了数据共享,促进了透明度,并提高了研究结果的可复制性.
- 通过促进合作和提供可访问的数据资源,这些软件包大大有助于推动AD研究.
更多相关视频
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
09:47DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
Published on: December 15, 2023
相关概念视频
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:12Statistical Software for Data Analysis and Clinical Trials
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...